Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.
Department of Medical Physics, Ludwig-Maximilians-Universität München, Munich, Germany.
Radiat Oncol. 2018 Jan 9;13(1):2. doi: 10.1186/s13014-017-0944-3.
Due to their favorable physical and biological properties, helium ion beams are increasingly considered a promising alternative to proton beams for radiation therapy. Hence, this work aims at comparing in-silico the treatment of brain and ocular meningiomas with protons and helium ions, using for the first time a dedicated Monte Carlo (MC) based treatment planning engine (MCTP) thoroughly validated both in terms of physical and biological models.
Starting from clinical treatment plans of four patients undergoing proton therapy with a fixed relative biological effectiveness (RBE) of 1.1 and a fraction dose of 1.8 Gy(RBE), new treatment plans were optimized with MCTP for both protons (with variable and fixed RBE) and helium ions (with variable RBE) under the same constraints derived from the initial clinical plans. The resulting dose distributions were dosimetrically compared in terms of dose volume histograms (DVH) parameters for the planning target volume (PTV) and the organs at risk (OARs), as well as dose difference maps.
In most of the cases helium ion plans provided a similar PTV coverage as protons with a consistent trend of superior OAR sparing. The latter finding was attributed to the ability of helium ions to offer sharper distal and lateral dose fall-offs, as well as a more favorable differential RBE variation in target and normal tissue.
Although more studies are needed to investigate the clinical potential of helium ions for different tumour entities, the results of this work based on an experimentally validated MC engine support the promise of this modality with state-of-the-art pencil beam scanning delivery, especially in case of tumours growing in close proximity of multiple OARs such as meningiomas.
由于氦离子束具有优越的物理和生物学特性,因此越来越多的人认为氦离子束是放射治疗中质子束的一种有前途的替代方法。因此,这项工作旨在使用首次基于专用蒙特卡罗(MC)的治疗计划引擎(MCTP),通过物理和生物学模型进行深入验证,首次对脑和眼脑膜瘤的质子和氦离子治疗进行体内比较。
从接受质子治疗的四名患者的临床治疗计划开始,这些患者的相对生物学有效剂量(RBE)固定为 1.1,分次剂量为 1.8 Gy(RBE),使用 MCTP 为质子(可变和固定 RBE)和氦离子(可变 RBE)优化了新的治疗计划,同时保持了源自初始临床计划的相同约束。根据计划靶区(PTV)和危及器官(OAR)的剂量体积直方图(DVH)参数以及剂量差异图,对生成的剂量分布进行了剂量学比较。
在大多数情况下,氦离子计划与质子计划提供了相似的 PTV 覆盖范围,并且一致的趋势是更好地保护 OAR。后一种发现归因于氦离子能够提供更陡峭的远端和侧向剂量下降,以及在靶区和正常组织中更有利的差异 RBE 变化。
尽管需要更多的研究来研究氦离子在不同肿瘤实体中的临床潜力,但基于经过实验验证的 MC 引擎的这项工作的结果支持了这种模式的潜力,尤其是在多个 OAR 附近生长的肿瘤(如脑膜瘤)的情况下。